Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding
- KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- EAS Gives Regulatory Crash Course
International food and nutrition policy consultancy EAS will be hosting a workshop entitled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch,’ October 9th, in Brussels.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Cognis Meets International Standard for Food Safety
The Cognis esterification plant at the Nutrition & Health Competence Center in Illertissen, Germany, has received the internationally renowned certificate of quality ISO 22000:2005 from the certification body DQS GmbH. The worldwide standard for food safety places rigorous demands on all process levels and along the whole chain of food production – from choosing raw materials and producing ingredients to manufacturing consumer products.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- Rasa Shastra a Potentially Poisonous Alternative
An article regarding the recent JAMA article concerning the presence of of lead, mercury and arsenic in ayurvedic medicinces, specifically for the practice of rasa shastra. Commentary from Dr. Robert Saper and Michael McGuffin (AHPA) is included.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- New Director General for Canada's NHPD
As a result of a competitive process, Michelle Boudreau has been selected as Director General of the Natural Health Products Directorate (NHPD) effective September 8, 2008.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award
The 2009 Frost & Sullivan European Functional Food & Beverage Microencapsulation Technology Innovation Award has been presented to GAT Food Essentials GmbH in recognition of its proprietary wowCAPS(R) technology.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates
Bio-Extraction Inc., has announced that it has completed the self-affirmation process to qualify its specialty canola protein products, Isolexx(TM) and Vitalexx(TM), as self-affirmed GRAS for their intended use in various foods and beverages, thus providing a basis for the sale of these products in the United States when commercial production commences in Q1 2010.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Synergy Flavors Invests in Sensory Flavor Profiling Research
Synergy Flavors has commissioned a new research program at North Carolina State University to study the sensory profiles of a range of protein ingredients.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
Synergy Flavors Inc., has announced their chocolate flavors offer a versatile solution for cocoa reduction and can be used as cocoa extenders.
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- NPI Daily - Top of The News for Nov. 20, 2009 - FDA Issues 22 Warning Letters to Website Operators
Frost & Sullivan Honours GAT Food Essentials GmbH With European Functional Food & Beverage Microencapsulation Technology Innovation Award; Synergy Flavors Invests in Sensory Flavor Profiling Research; FDA Issues 22 Warning Letters to Website Operators; Nordic Naturals Ultimate Omega™ First Fish Oil to Participate in NFL/NFLPA Sports Nutrition Label Certification Program; BioExx Achieves Self-Affirmed GRAS Status for Protein Isolates; New Organic Berry Whole Food Energy Bar from Amazing Grass Delivers Whole Food Nutrition; Beat Crazy Cocoa Prices with Synergy's Chocolate Flavors
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Heart Health Alert: Niacin May Reverse Hardening of the Arteries
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Spotlight on Savory Side Dishes
- Another Reason to Choose Healthy Lifestyle Habits
- Another Reason to Choose Healthy Lifestyle Habits
|
JARED ROBERT WHEAT, 36, of Alpharetta, Georgia; STEPHEN DOUGLAS SMITH, 40, of Duluth, Georgia; TOMASZ HOLDA, 45, of Duluth, Georgia; SERGIO OLIVEIRA, 48, of Hoschton, Georgia; and “HI-TECH PHARMACEUTICALS, INC.,” a company based in Norcross, Georgia, pleaded guilty today to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
Rodney G. Benson, Special Agent in Charge of the DEA Atlanta Field Division (AFD) said, “The diversion of pharmaceutical products over the internet continues to be a major concern. Rogue internet sites are in the business to make millions in illegal sales, not to benefit the public. Today's guilty pleas illustrate how DEA and our local, state and federal law enforcement counterparts are committed to eradicating this problem.”
United States Attorney David E. Nahmias said of the pleas, “These defendants set up an offshore manufacturing facility where, in unsanitary conditions, they reproduced leading pharmaceutical products for importation into the United States, all without FDA approval or licensing from the rightful patent holders. Their motive in flouting the law, violating patents and exposing their customers to unknown health risks was greed, pure and simple. I commend the FDA and the DEA for their thorough investigation in this case. The Department of Justice and these agencies will continue to work hard to protect American consumers from such fraudsters.”
FDA Office of Criminal Investigations Special Agent In Charge David Bourne said, “As in this conviction, the FDA's Office of Criminal Investigations actively pursues those who deceive the public by manufacturing and selling unapproved and unregulated medications which may pose risks to the health of consumers. We are committed to investigating and preventing those who use trickery and deceit to illegally and unscrupulously sell medications over the internet at the expense of the public health.”
According to Nahmias and the information presented in court: The defendants in this case, in furtherance of their conspiracy, established a manufacturing facility in a small office park in rural Belize. Inside what was essentially a four-room home, the defendants produced unauthorized generic versions of such popular prescription pharmaceuticals as Xanax, Valium, Ambien, Vioxx, Zoloft, Viagra, and Cialis. The manufacturing processes complied with none of the sanitary, hygienic, or quality-control regulations issued by the FDA, nor had the defendants obtained approval from the FDA or licenses from the patent-holders to make such drugs. Nonetheless, the defendants made the drugs and marketed them, primarily via the internet, to customers in the United States and elsewhere. The drugs were made available without prescription and also without disclosure of the unsanitary manufacturing conditions. The defendants realized millions of dollars of sales before the scheme was initially disrupted by Belizean authorities and ultimately ended by U.S. authorities.
United States District Court Judge Jack T. Camp accepted today's guilty pleas in federal court in Newnan. All defendants pleaded to conspiring to violate federal prohibitions against mail and wire fraud and the importation and distribution of adulterated, unapproved, and mislabeled drugs. This conspiracy offense carries a maximum penalty of five years in prison and a maximum fine of $250,000 (maximum of five years on probation and a fine of the greater of $500,000 or double the fraud amount for the corporate defendant). Sentencing for the defendants is now set for October 21, 2008, before Judge Camp. In determining the actual sentence, the Court will consider the United States Sentencing Guidelines, which are not binding but provide appropriate sentencing ranges for most offenders.
This case was investigated by the agents of the Drug Enforcement Administration (DEA), and the U.S. Food and Drug Administration (FDA) with overseas assistance from Belizean law enforcement authorities.
Assistant United States Attorneys Randy Chartash, Douglas Gilfillan, and Robert McBurney prosecuted the case.
DEA AFD SAC Benson encourages parents, along with their children, to educate themselves about the dangers of legal and illegal drugs by visiting DEA’s interactive websites at www.justhinktwice.com and www.dea.gov
|